The design and application of DNA chips for early detection of SARS-CoV from clinical samples

Zhou, Yi; Yang, Ren; Tao, Sheng Ce; Li, Ze; Zhang, Qiong; Gao, Hua; Zhang, Zhi Wei; Du, Jiajun; Zhu, Pei; Ren, Li; Zhang, Liang; Wang, Dong; Guo, Liting; Wang, Yan Bin; Guo, Yong; Zhang, Yan; Zhao, Chuan; Wang, Can; Jiang, Di; Liu, Yan Hua; Yang, Hui; Li, Rong; Yan, Zhao; An, Shuang; Li, Zhe; Fan, Xiao Dong; Wang, Jian Wei; Cao, Yun; Liu, Ou; Zheng, Zhong; Zuo, Huancong; Shan, Quan Zhong; Ruan, Li; Lu, Zhan; Hung, Tao; Cheng, Jing

doi:10.1016/j.jcv.2004.10.019

Cited by 11 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SARS-CoV and SARS-CoV-2 exhibit a very high genetic similarity; both include in their genome four main structural proteins: S, M, E, and N. The SARS-CoV-2 gene S has approximately 75% of the same nucleotide sequences as SARS-CoV, and both viruses bind to host cells using the human angiotensin-converting enzyme 2 receptors. 84,85 For SARS-CoV, several vaccines were tested in animal models, including recombinant S-protein-based vaccines, attenuated and whole inactivated vaccines, and vectored vaccines, but no vaccine was developed. 86 Studies from SARS-CoV have been a reference for the development of COVID-19 vaccines for which multiple strategies have been adopted, most of which target the S protein.…”

Section: Development Of Vaccine Against Sars and Covid-19mentioning

confidence: 99%

Risk management and communication plans from SARS to COVID‐19 and beyond

Recchia

Aloisi

Zizza

2022

Health Planning & Management

View full text Add to dashboard Cite

Objective Nowadays, due to globalisation, the likelihood that infectious diseases spread rapidly is extraordinarily high. SARS and COVID‐19 are two diseases of the Coronavirus family, which developed in China and then spread internationally, causing global public health emergencies. This study investigates the role that risk management and communication systems played in mitigating these emergencies, to establish how they should be improved in the future. Methods A narrative review was carried out to investigate different knowledge domains, such as risk management and communication, risk assessment and indicators, epidemiological and clinical data, diagnostic methods, vaccines, public health and social measures. Results On one side, risk management systems assess the main data, knowledge, and indicators on epidemiology, diagnostics, and vaccines (science‐based); on the other side, they apply public health and social measures (socially‐based). Decision‐makers, in fact, implement their actions by constantly balancing these two sides (policy‐based). Conclusions A correct crisis management approach should support the governance of pandemics, by harmonising the actual risks assessed by experts with those perceived by the general population. It should incorporate not only the biological, but even the environmental, social and economic aspects of virus emergencies, towards establishing a suitable framework to deal with possible future pandemics.

show abstract

Section: Development Of Vaccine Against Sars and Covid-19mentioning

confidence: 99%

Risk management and communication plans from SARS to COVID‐19 and beyond

Recchia

Aloisi

Zizza

2022

Health Planning & Management

View full text Add to dashboard Cite

show abstract

“…One of the crucial clinical questions asked about COVID-19 is whether this is a condition limited to the respiratory and gastrointestinal sites, or whether there is dissemination to other organs. In the 2003 SARS outbreak, there were two publications which found evidence of viral RNA in the blood, 77,78 and one publication demonstrating viral RNA in 33% of patients with MERS-CoV infection 79 ; however, there has been no published information on the other human coronaviruses. Although there has been interest in exploring the multi-organ tropism of this virus, 80 in view of the time frame of organs sampled from 20 to 81 days after infection correlation with damage due to direct virus interaction needs to be examined more closely.…”

Section: Dissemination and Transmission Viraemiamentioning

confidence: 99%

Pathophysiology of infection with SARS‐CoV‐2—What is known and what remains a mystery

Sridhar

Nicholls

2021

Respirology

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused extensive disruption and mortality since its recent emergence. Concomitantly, there has been a race to understand the virus and its pathophysiology. The clinical manifestations of COVID-19 are manifold and not restricted to the respiratory tract. Extrapulmonary manifestations involving the gastrointestinal tract, hepatobiliary system, cardiovascular and renal systems have been widely reported. However, the pathophysiology of many of these manifestations is controversial with questionable support for direct viral invasion and an abundance of alternative explanations such as pre-existing medical conditions and critical illness. Prior research on SARS-Co-V and NL63 was rapidly leveraged to identify angiotensin-converting enzyme 2 (ACE2) receptor as the key cell surface receptor for SARS-CoV-2. The distribution of ACE2 has been used as a starting point for estimating vulnerability of various tissue types to SARS-CoV-2 infection. Sophisticated organoid and animal models have been used to demonstrate such infectivity of extrapulmonary tissues in vitro, but the clinical relevance of these findings remains uncertain. Clinical autopsy studies are typically small and inevitably biased towards patients with severe COVID-19 and prolonged hospitalization. Technical issues such as delay between time of death and autopsy, use of inappropriate antibodies for paraffin-embedded tissue sections and misinterpretation of cellular structures as virus particles on electron micrograph images are additional problems encountered in the extant literature. Given that SARS-CoV-2 is likely to circulate permanently in human populations, there is no doubt that further work is required to clarify the pathobiology of COVID-19.

show abstract

“…Wang and De Risi and colleagues developed a number of arrays for detection of known viral and emerging viral pathogens using hybridization to species-specific oligonucleotide probes [57,58,59] and using advanced bioinformatics analysis tools to reveal pathogen-specific signal patterns [60]. Similar methodologies have been used by these and other groups to identify meningitis-associated and emerging pathogens, including the severe acute respiratory syndrome (SARS) coronavirus [61,62,63,64]. Here we present development and validation of a meningitis diagnostic microarray; it’s reconfiguration onto the Alere Arraytube TM (Alere Technologies GmbH, Jena, Germany) platform and provide recommendations for its use in a diagnostic setting.…”

Section: Introductionmentioning

confidence: 99%

Development and Assessment of a Diagnostic DNA Oligonucleotide Microarray for Detection and Typing of Meningitis-Associated Bacterial Species

et al. 2018

View full text Add to dashboard Cite

Meningitis is commonly caused by infection with a variety of bacterial or viral pathogens. Acute bacterial meningitis (ABM) can cause severe disease, which can progress rapidly to a critical life-threatening condition. Rapid diagnosis of ABM is critical, as this is most commonly associated with severe sequelae with associated high mortality and morbidity rates compared to viral meningitis, which is less severe and self-limiting. We have designed a microarray for detection and diagnosis of ABM. This has been validated using randomly amplified DNA targets (RADT), comparing buffers with or without formamide, in glass slide format or on the Alere ArrayTubeTM (Alere Technologies GmbH) microarray platform. Pathogen-specific signals were observed using purified bacterial nucleic acids and to a lesser extent using patient cerebral spinal fluid (CSF) samples, with some technical issues observed using RADT and glass slides. Repurposing the array onto the Alere ArrayTubeTM platform and using a targeted amplification system increased specific and reduced nonspecific hybridization signals using both pathogen nucleic and patient CSF DNA targets, better revealing pathogen-specific signals although sensitivity was still reduced in the latter. This diagnostic microarray is useful as a laboratory diagnostic tool for species and strain designation for ABM, rather than for primary diagnosis.

show abstract

The design and application of DNA chips for early detection of SARS-CoV from clinical samples

Cited by 11 publications

References 12 publications

Risk management and communication plans from SARS to COVID‐19 and beyond

Risk management and communication plans from SARS to COVID‐19 and beyond

Pathophysiology of infection with SARS‐CoV‐2—What is known and what remains a mystery

Development and Assessment of a Diagnostic DNA Oligonucleotide Microarray for Detection and Typing of Meningitis-Associated Bacterial Species

Contact Info

Product

Resources

About